Results 211 to 220 of about 3,593,458 (250)
ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta +5 more
wiley +1 more source
Multiple Primary Malignancies Involving Papillary Thyroid Carcinoma: A Three‐Case Series
Patients with papillary thyroid carcinoma may develop distinct additional primary malignancies. New lesions or lymphadenopathy should not be presumed to represent metastatic PTC without tissue confirmation, emphasizing accurate diagnosis, multidisciplinary evaluation, and individualized treatment.
Katayoon Ghasemi +2 more
wiley +1 more source
ABSTRACT In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected ...
Wang Zhenyan, Wang Yan
wiley +1 more source
Duodenal neuroendocrine tumor after bilateral breast cancer with type 1 neurofibromatosis: a case report. [PDF]
Fujiwara S +5 more
europepmc +1 more source
ABSTRACT This case highlights key laboratory red flags and a failure to respond to standard treatment, both of which should prompt urgent investigation for occult malignancy in patients presenting with cancer‐related microangiopathic hemolytic anemia (CR‐MAHA).
Danijela Jovanovic +4 more
wiley +1 more source
ABSTRACT Background Salivary gland carcinomas are uncommon malignancies with various histological subtypes harboring fusion genes. The EWSR1::ATF1 fusion gene, resulting from a translocation between chromosomes 12 and 22, is frequently observed in hyalinizing clear cell carcinoma (HCCC). However, the role of this fusion gene in HCCC oncogenesis remains
Yuri Hirai +13 more
wiley +1 more source
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree +14 more
wiley +1 more source
Bisphosphonates are widely used to treat osteoporosis and to manage bone metastases in patients with breast cancer. Nitrogen‐based bisphosphonates may also broadly reduce cancer risk, but evidence remains inconsistent. This large population‐based data linkage study in women aged > 50 years found that, compared to no use of osteoporosis medicines ...
Karen M. Tuesley +7 more
wiley +1 more source
Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens +14 more
wiley +1 more source
Ultrasound-Guided Regional Anesthesia Using a Mixture of Dexamethasone, Dexmedetomidine, and 0.2% Levobupivacaine for Bilateral Breast Cancer Surgery Under a Spontaneous Breathing Opioid-Free Anesthesia: A Case Report. [PDF]
Falso F +4 more
europepmc +1 more source

